Caribou Biosciences, Inc.

CRBU

NASDAQ

Healthcare

Biotechnology

Berkeley, CA, US147 employeescariboubio.com

$1.94

-0.06(-2.76%)

Mkt Cap $187M

$0.73

$2.84

52-Week Range

At a Glance

AI-generated

Caribou Biosciences, Inc.

Revenue breakdown: Reportable Segment (100%).

8-K

Caribou Biosciences received FDA RMAT designation for CB-011 allogeneic anti-BCMA CAR-T therapy in r/r multiple myeloma based on promising phase 1 dose escalation data showing 92% ORR in BCMA-naïve patients.

$187M

Market Cap

$11M

Revenue

-$151M

Net Income

Employees147

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segment100%($21M)

Revenue by Geography

US88.6%($19M)

Non Us11.4%($2M)

Activity

What Changed Recently

Financial Results

Mar 4, 2026

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the

Regulation FD

Mar 30, 2026

. The information in this Item 7.01, including the accompanying Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange

Peer Companies

Company	Price	Change	Market Cap	P/E
ALLOAllogene Therapeutics, In...	$2.50	-2.54%	$608M	-2.8
ENTAEnanta Pharmaceuticals, I...	$13.15	+1.39%	$305M	-3.8
FHTXFoghorn Therapeutics Inc.	$4.93	+0.61%	$289M	-4.3
IVAInventiva S.A.	$5.48	+0.92%	$285M	-1.8
OBIOOrchestra BioMed Holdings...	$4.26	-1.81%	$249M	-3.5
PRLDPrelude Therapeutics Inco...	$3.51	+1.74%	$196M	-2.0
TNYATenaya Therapeutics, Inc.	$0.70	+2.16%	$116M	-1.3
HUMAHumacyte, Inc.	$0.65	+9.61%	$102M	-3.6

Analyst View

Company Profile

CIK0001619856

ISINUS1420381089

CUSIP142038108

Phone510 982 6030

Address2929 7th Street, Berkeley, CA, 94710, US

SEC EDGAR